Expert interview with Dr. Jur ten Berg about dual antithrombotic therapy with Dabigatran in AF patients post PCI. In the interview he focuses mainly on new subanalyses, presented at ACC

Does the Discontinuation of ASA in the Warfarin-TT Arm Influence the Treatment Outcomes Vs Dabigatran-DT?

Landmark analysis

• What treatment regimens were compared in the RE-DUAL PCI trial
• Does the discontinuation of aspirin in the warfarin-TT arm influence the treatment outcomes vs dabigatran-DT?
• How do these results fit with the current European guidelines in this setting?

Based on the RE-DUAL PCI data, what would be the recommended dose of dabigatran for our elderly patients as part of a dual therapy strategy?

Age

• Is dabigatran dual therapy suitable for both younger and elderly patients with AF undergoing PCI?
• Based on the RE-DUAL PCI data, what would be the recommended dose of dabigatran for our elderly patients as part of a dual therapy strategy?

What are the concerns for patients with AF who need to undergo a PCI with additional complicating factors?

PCI complexity

• What does the PCI complexity subanalysis add to our understanding on how to manage patients with AF post-PCI?

How does TTR with warfarin-TT impact treatment outcomes, when compared with dabigatran-DT?

TTR analysis

• How does TTR with warfarin-TT impact treatment outcomes, when compared with dabigatran-DT